close
MENU
How to guide
How to guide
Home
NBR Marketplace
The NBR List
NBR Video

Categories

General Business Investment Economics Te Ao Māori Politics Infrastructure Australia Tech & Innovation Finance Law Professional Services Primary Industries Retail Property Deals Marketing & Media Tourism Energy Luxury Property Aviation News Comings & Goings

Analysis

All Economy Matters Edwards on Politics Hunter’s Corner Last Word Margin Call On the Money Shoeshine Underarm NBR Focus

Featured

The NBR Podcast Morning Brew The Grind Entrepreneurs Your Business Beehive Banter Toil & Trouble Market Outlook Dollars & Sense Local Edge Private Bin Audio Articles Podcasts NZ Aviation News Back Issues NBR Radar (Archive) Opinion (Archive) NBR Rich List (Archive)
Investment
3 mins to read
1

Bogoievski and K1W1 help local biotech firm address US Covid surveillance market

Parnell-based company seek global manufacturing expansion of its antibody tests.

Dita De Boni Thu, 14 Apr 2022

An investment led by former Morrison & Co chief executive Marko Bogoievski and Sir Stephen Tindall’s investment arm K1W1 into local biotech firm Pictor will see the Kiwis partner with a US laboratory to use its test that allows people to see what kind of antibodies they have in the fight against

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
View terms and conditions.
Individual
Group membership
NBR Marketplace

Smartphone Only Subscription

NZ$29.95 / monthly

Monthly Premium Online Subscription

NZ$49.95 / monthly

Smartphone Only Annual Subscription

NZ$299.00 / yearly

Yearly Premium Online Subscription

NZ$499.00 / yearly

Premium Group Membership 10 Users

NZ$385+GST / monthly

$38.5 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$660+GST / monthly

$33 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1375+GST / monthly

$27.5 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$2100+GST / monthly

$21 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$999.00 / yearly

Already have an account? Login
Dita De Boni Thu, 14 Apr 2022
Contact the Writer: dita@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Tags
K1W1 Pictor Mobility Health Covid-19 coronavirus Marko Bogoievski

Free News Alerts

Sign up to get the latest stories and insights delivered to your inbox – free, every day.

I’m already subscribed/joined
Related News
General Business
1

Pictor to launch new Covid antibody test next month
General Business

Diagnostics firm Pictor expects revenue boom from Covid partnership
1

Fund tries to counteract deep-seated bias in investment decisions

Free News Alerts

Sign up to get the latest stories and insights delivered to your inbox – free, every day.

I’m already subscribed/joined
Related News
General Business
1

Pictor to launch new Covid antibody test next month
General Business

Diagnostics firm Pictor expects revenue boom from Covid partnership
1

Fund tries to counteract deep-seated bias in investment decisions

Bogoievski and K1W1 help local biotech firm address US Covid surveillance market
Investment,
91229
true
Subscribe Login